Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment. by Pyngottu, Ashima et al.
Ac
ce
pte
d M
an
us
cri
pt
 
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of 
America. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which 
permits non-commercial reproduction and distribution of the work, in any medium, provided the 
original work is not altered or transformed in any way, and that the work is properly cited. For 
commercial re-use, please contact journals.permissions@oup.com 
Predictors of virological failure and time to viral suppression of first line integrase 
inhibitor based antiretroviral treatment 
Ashima Pyngottu
,12*
, Alexandra U. Scherrer
1,2*
, Roger Kouyos
1,2
, Michael Huber
2
, Hans 
Hirsch
3
, Matthieu Perreau
4
, Sabine Yerly
5
, Alexandra Calmy
5
, Matthias Cavassini
6
, Marcel 
Stöckle
3
, Hansjakob Furrer
7
, Pietro Vernazza
8
, Enos Bernasconi
9
, Huldrych F. Günthard
1,2 
and the Swiss HIV Cohort Study 
*authors contributed equally  
 
 
1 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 
Zurich, Switzerland  
2 Institute of Medical Virology, University of Zurich, Zurich, Switzerland  
3 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, 
University of Basel, Basel, Switzerland  
4 University of Lausanne, Lausanne, Switzerland  
5 Laboratory of Virology and Division of Infectious Diseases, Geneva University Hospital, 
University of Geneva, Geneva, Switzerland  
6 Division of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland  
7 Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article/doi/10.1093/cid/ciaa1614/5937176 by guest on 26 O
ctober 2020
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
7
3
9
5
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Ac
ce
pte
d M
an
us
cri
pt
 
2 
 
Switzerland  
8 Division of Infectious Diseases, Cantonal Hospital St Gallen, St. Gallen, Switzerland 
 
9 Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland  
 
Corresponding author: 
Prof. Dr. med. Huldrych Günthard, Division of Infectious Diseases and Hospital 
Epidemiology, University Hospital Zürich, 8091 Zürich, Switzerland 
E-mail: huldrych.guenthard@usz.ch,  
Tel:  +41 44 255 33 22 
 
Alternate corresponding author: 
Dr. Alexandra Scherrer, Division of Infectious Diseases and Hospital Epidemiology, 
University Hospital Zürich, 8091 Zürich, Switzerland 
Email: alexandra.scherrer@usz.ch 
Tel: +41 44 634 19 13 
 
40-word summary: Integrase strand transfer inhibitor-based therapies are effective first-line 
treatments of HIV-infection. Among 1419 patients, we have identified a high baseline viral 
load, low CD4 cell counts and an AIDS defining event before treatment initiation as 
predictors for treatment failure.  
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Abstract 
Background 
Integrase strand transfer inhibitors (InSTIs) are recommended for first-line treatment of HIV-
infection. We identified risk factors, including baseline minor InSTI resistance mutations, for 
treatment failure of InSTI-based regimens. 
Methods 
We studied time to treatment failure and time to viral suppression among 1419 drug-naive 
patients in the Swiss HIV Cohort Study.  
We performed Cox regression models adjusted for demographic factors, baseline HIV 
RNA/CD4 cell counts, AIDS defining events and the type of InSTI.  
In 646 patients with a baseline genotypic resistance test of the integrase, we studied the 
impact of minor integrase resistance mutations.  
Results 
We observed 121 virological failures during 18’447 person-years of follow-up. A baseline 
viral load ≥100’000 cps/mL (multivariable Hazard Ratio (mHR): 2.2, 95% CI: 1.3-3.6) and 
an AIDS defining event (mHR: 1.8, 95% CI: 1.1-3.0) were associated with treatment failure. 
CD4 counts between 200-500 cells/µL (mHR: 0.5, 95% CI: 0.3-0.8) and >500 cells/µL 
(mHR: 0.4, 95% CI: 0.2-0.7) were protective. Median [IQR] time to viral suppression was 50 
[29,107] days. Time to suppression was shorter in lower viral load strata (mHR: 0.7, 95% CI: 
0.6-0.8) and in dolutegravir-based therapy (mHR: 1.2, 95% CI: 1.0-1.4). Minor resistance 
mutations were found at baseline in 104/646 (16%) patients with no effect on treatment 
outcome.  
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Conclusion  
Among drug-naïve HIV-infected individuals treated with InSTI-based regimens, factors 
associated with treatment failure, in particular high viral load and low CD4 counts remain 
similar to older treatments. Minor InSTI resistance mutations had no impact in this large 
observational cohort.  
 
Keywords: HIV, integrase strand transfer inhibitors, drug resistance, minor drug resistance 
mutations, treatment outcome 
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Introduction 
Integrase strand transfer inhibitor (InSTI)-based antiretroviral therapies are recommended for 
first-line treatment of most individuals infected with HIV-1 [1]. These potent combinations 
achieve sustained virological suppression and treatment failures are rare. Nonetheless, it is 
important to identify patients with increased risk for therapy failure as it jeopardizes the long-
term treatment success and facilitates the emergence of drug resistance. 
Failure of potent antiretroviral therapy is associated with several factors [2, 3]. In phase III 
trials, InSTI-based regimens have proven to be at least equally potent as or superior to other 
antiretroviral regimens [4-7]. The second generation InSTIs dolutegravir (DTG) and 
bictegravir (BIC), have a high potency even among individuals with a high viral load or low 
CD4 count at baseline [5, 8-10]. Phase III trials showed that baseline plasma HIV-RNA did 
not affect DTG-based therapy, while for raltegravir the impact of baseline viral load is 
discussed controversially [8, 11]. Smaller clinical studies that encompassed drug naïve and 
treatment-experienced patients, suggested that older age [12, 13], lack of adherence [14], 
origin from a high prevalence country, injection drug use and a low CD4 count at baseline 
[13] increased the risk for failure of InSTI- based therapy. 
Another possible reason for the failure of antiretroviral treatment is the presence of 
pretreatment drug resistance associated mutations (RAMs), mostly transmitted drug 
resistance mutations TDRs) [2, 15, 16]. Although large studies did not find a correlation 
between virological failure in drug naïve individuals on InSTIs and the presence of TDRs 
[17, 18], some case reports suggest otherwise [19-21]. In European studies, less than 1% of 
drug naïve or recently infected individuals had major InSTI-mutations [22-26]. However, 2% 
to 17.3% had minor RAMs that often occur as polymorphisms of the HIV-wild type [22-26]. 
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Although they are considered to have little effect on InSTI susceptibility, there is lack of 
research to which extent they affect InSTI-based treatments [27-29]. 
The objective of this study is to identify risk factors for treatment failure of InSTI-based 
combined antiretroviral treatment (cART) in drug naïve HIV-1 infected individuals from the 
Swiss HIV Cohort Study (SHCS) and to assess the impact of minor InSTI RAMs on 
treatment outcome. 
Methods 
Study population/study design 
We used data from the Swiss HIV Cohorts Study (SHCS) and the SHCS drug resistance 
database. The SHCS is a nationwide, multicenter longitudinal study established in 1988. The 
SHCS population is highly representative as it encompasses 75% of all the patients receiving 
antiretroviral treatment and 69% of the people with AIDS living in Switzerland. The drug 
resistance database includes all genotypic resistance tests (GRT) conducted in Switzerland 
and is linked to the clinical database [30]. The SHCS continuously enrolls HIV infected 
individuals aged 18 years or older independent of the stage and severity of the disease. Data 
is collected using a structured form at registration and on the semi-annual visits. The ethical 
committees of all participating institutions have approved the SHCS and written informed 
consent is obtained from all participants [30, 31]. 
Patient selection 
We included drug-naïve HIV infected individuals from the SHCS that started an InSTI based 
antiretroviral treatment between 1 January 2006 and 31 December 2018. If the HIV-RNA-
load was not measured in a patient after treatment start, that patients was excluded.   
To analyze pretreatment resistance patterns, we identified patients who received a baseline 
GRT including the integrase using the SHCS drug resistance database. 
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Definition of drug resistance mutations 
Minor and major RAMs were defined based on the IAS-USA recommendations [36] and the 
Stanford University HIV Drug Resistance Database Version 8.9-1 
(https://hivdb.stanford.edu). The following mutations from the IAS-USA recommendations 
were included; major mutations: T66I, E92Q, G118R, F121Y, G140R, Y143CHR, S147G, 
Q148HKR, N155H, R263K; minor mutations: T66AK, L74M, E92G, T97A, E138AKT, 
G140ACS, S153FY. 
The following RAMs from the HIV Drug Resistance Database with a HIVdb score ≥30 were 
also defined as major mutations: E92V, Y143AGK, Q146P, V151L, and N155S. Mutations 
with a penalty score ≥10 and <30 were in addition to the IAS-USA recommendations 
included as minor mutations: H51Y, L74FI, E95K, P142T, Q148N, V151I, N155D, E157Q, 
G163KR, S230R, D232N.  
Outcome 
Our primary endpoints were time to viral suppression and time to virological failure. The 
follow-up time was defined as the period from the start of the InSTI based regimen until the 
end of InSTI therapy. Data was censored at the last visit, the end of InSTI-based therapy or at 
the patient’s death. Data was not censored when the patient changed from one InSTI to 
another or when NRTIs background ART was modified/adapted. 
Time to viral suppression was defined as the time from treatment begin to the first viral load 
<50 HIV-RNA copies/mL. Virological failure was defined as follows:  
(1) Two consecutive RNA values >50 copies/mL after at least 180 days of continuous 
treatment  
(2) One value >50 copies/mL after 180 days of treatment, followed by treatment change to 
another drug class or  
(3) No viral suppression < 50 copies/mL after more than 180 days of treatment.  
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Statistical analysis 
We used Stata/SE version 15.1 for the statistical analysis. We performed univariable and 
multivariable Cox regressions to identify the effect of baseline characteristics on time to viral 
suppression and time to virological failure. The following factors were considered: age at 
therapy start, ethnicity, transmission risk group, HIV-RNA load, CD4 cell count, history of 
an AIDS defining event at or before treatment start, the type of InSTI administered and the 
presence of InSTI RAMs. Another factor included was the financial independence of the 
individual: patients whose salary generated more than 50% of their income were considered 
more financially independent than those who predominantly relied on other sources for their 
income such as unemployment benefits. In the multivariable model, factors with a p-value 
<0.1 in the univariable model and previously described risk factors for treatment outcome 
(age at treatment start, ethnicity, transmission risk group, the type of InSTI) were included. 
Continuous variables were categorized if likelihood ratio tests showed significant departure 
from linearity. Levels of self-reported adherence between patients that experienced 
virological failure and those without treatment failure were compared using the Pearson chi2-
test. Self-reported adherence is assessed every 6 months, the data closest to the treatment 
failure or censoring was chosen [32]. We tested the proportional hazard assumption by 
calculating Schönfeld residuals and by using graphical procedures. No violations of the 
proportionality hazard assumption were detected. The level of significance was considered at 
p-value <0.05. To assess whether our results differed by the administered InSTI, we 
performed additional analyses where we stratified by the type of  InSTI. Additionally, we 
studied the subgroup of patients with a baseline viral load >100’000 copies/mL in detail. 
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Results 
Study population 
We identified 1’472 HIV-1 infected drug naive individuals who started an InSTI based cART 
(Figure 1). We excluded 4 (0.3%) patients, as follow-up data was not available and 49 (3%) 
patients because of missing HIV-RNA values. Finally, 1’419 out of 1’472 (96%) patients 
were included to study the time to viral suppression and to virological failure. The InSTI 
most often administered was DTG (n=925, 65%), followed by EVG (n=281, 20%) and RTG 
(n=213, 15%). None of the participants received BIC, which was introduced in Switzerland 
only in 2018. Table 1 shows the baseline characteristics of our study population. Of the 1,419 
individuals in our study, 646 (45%) had a baseline GRT including the integrase performed 
and 378 (27%) had a baseline viral load ≥100’000 copies/mL.  
Time to virological failure 
During the 18’447-person-years of follow-up, we observed 121 virological failures. Twenty-
three of 121 patients had a viral load >1000 HIV-RNA copies/mL at the time of virological 
failure. Nine of 121 patients did not reach viral suppression within 180 days and all others 
failed treatment after having achieved viral suppression. Figure 2 and in the Supplementary 
Table 1 summarize the results of the multivariable analysis of time to virological failure. A 
hazard ratio (HR) >1 implies more virological failures in the analyzed group compared to the 
reference group.  
Among patients with treatment failure a report of missing at least one dose of ART in the past 
month was more frequent (9 out of 121 (7.4%) vs 41 out of 1’298 (3.6%), p-exact=0.049) 
than among non-failing patients. 
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A CD4 cell count at baseline above 200 cells/µL was associated with fewer failures (<200/ul: 
Reference, 200-500/µL: mHR 0.5, 95% CI 0.3-0.8; >500/µL: mHR: 0.4, 95% CI 0.2-0.7) 
(Figure 3). An HIV-RNA load ≥100’000 copies/mL was associated with failures (mHR: 2.2, 
95% CI 1.3-3.6) as compared to a viral load <10’000 copies/mL (Figure 3). In addition, 
patients that experienced an AIDS defining event had an increased chance for failure (mHR: 
1.8, 95% CI 1.1-3.0). The two most common AIDS defining events were pneumocystis 
pneumonia and esophageal candidiasis, which occurred in 45 (3.2%) and 29 (2.0%) of 1419 
patients, respectively. 
A sub-analysis showed that the results were comparable when the data was censored at the 
change of any substance in the treatment regimen, not only at the end of InSTI-based therapy 
(Supplementary Table 2). The results were similar when the Cox regression analysis was 
restricted to patients on DTG (Supplementary Table 3), baseline HIV-RNA ≥100’000 
copies/mL was associated with virological failure (mHR: 2.2, 95% CI: 1.1-4.4) while a CD4 
count >200 was protective (200-500 cells/µL mHR: 0.4, 95% CI:0.2-0.8, >500 cells/µL 
mHR: 0.4, 95% CI: 0.2-0.8). 
In the sub-analysis that included patients with a baseline viral load ≥100’000 copies/mL 
(Supplementary Table 4), only the CD4 count at baseline affected treatment outcome. 
Patients with at least 200 CD4 cells/µL had a lower chance for failure than those with < 200 
cells/µL (200-500 cells/µL: mHR 0.3, 95% CI: 0.2-0.6, >500 cells/µL: 0.2, 95% CI: 0.05-0.6)  
Time to viral suppression 
Median [IQR] time to viral suppression was 50 [29,107] days and the median time between 
two HIV-RNA measurements in the first year was 10.4 [8.52, 12.96] weeks. Figure 2 and 
Supplementary Table 1 show the results of the analysis for time to viral suppression . A 
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hazard ratio (HR)>1 implies a shorter time to viral suppression in the analyzed group 
compared to the reference group.  
A viral load ≥10’000 copies/mL at baseline was associated with longer time to suppression 
compared to a viral load <10’000 copies/mL (10’000-99’999 copies/mL: mHR: 0.7, 95% CI: 
0.6-0.8, ≥100’000 copies/mL: mHR: 0.5, 95% CI: 0.4-0.6) (Figure 3). Patients on a first-line 
therapy with DTG (mHR: 1.2, 95% CI: 1.0-1.4) and financially independent patients had a 
shorter time to viral suppression (mHR: 1.6, 95% CI 1.1-2.4).  
Among patients with an HIV-RNA load ≥100’000 copies/mL at baseline, time to viral 
suppression was shorter with a baseline CD4 count >500/µL (mHR: 1.5, 95% CI: 1.0-2.2). 
Time to suppression was also shorter under a first-line therapy with DTG (mHR: 1.7, 95% 
CI: 1.2-2.3) than under therapy with other InSTIs.  
In the sub-analysis that included only patients on DTG time to viral suppression was 
increased in individuals with a viral load ≥10’000 copies/ml (10’000-99’999 copies/mL 
mHR: 0.8, 95% CI: 0.7-0.9, ≥100’000 copies/mL mHR: 0.6, 95% CI 0.5-0.7) and decreased 
in financially independent patients (mHR: 1.7, 95% CI:1.1-2.6) . 
Across the analyses, other demographic factors and the mode of transmission were not 
significantly associated with the virologic outcome. 
Impact of InSTI resistance associated minor mutations at baseline  
Among 646 patients with a pretreatment GRT, no one had major mutations. We detected 
minor mutations in 104 (16%) patients. The most common mutations were L74I (n=65, 
8.55%), V151I (n=14, 1.89%) and E157Q (n=14, 1.60%). All other RAMs were present in 
less than 1.6% of the cases (see Supplementary Table 5). The highest prevalence of L74I was 
found among subtype A (14 of 24 patients, 41.2%) and subtype G (5 of 12 patients, 41.7%) 
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infections. L74I occurred among 30 of 364 (8.2%) of subtype B infections. We did not 
observe an effect of the presence of minor InSTI RAM on both therapeutic outcomes studied 
(Time to failure: mHR: 0.9 , 95% CI 0.4-1.9, Time to suppression: mHR: 1.0, 95% CI 0.8-
1.2) (Figure 4). Most of the other risk factors found to correlate with the outcome in the 
primary analysis affected the therapeutic outcome in the subgroup (Supplementary Table 6).  
Discussion 
To our knowledge, this is the first observational study to analyze the risk factors for failing 
InSTI-based therapy in drug naïve HIV-1 infected individuals, including minor integrase 
RAMs. 
In general, response to InSTI-based first-line treatment of drug naive patients was excellent. 
Nevertheless, a high viral load and/or a low CD4 count at baseline was associated with more 
treatment failures and lower time to suppression. Among patients presenting with a baseline 
viral load ≥10’000, DTG therapy showed a superior activity in decreasing the time to viral 
suppression than other InSTIs studied. The superiority of DTG over first generation InSTIs 
and other antiretroviral drugs in the treatment of drug naïve patients with a high viral load 
was shown by various randomized controlled studies [4-7]. However, contrary to the findings 
in those trials, high viral load / low CD4 count at baseline also jeopardized treatment success 
among participants on DTG in our study. These findings are in line with the NAMSAL and 
ADVANCE trials, which found evidence that treatment success on DTG is impaired among 
patients with a baseline viral >100’000 copies/mL [33, 34]. Transmitted and acquired NNRTI 
drug resistance are important drivers to change to DTG in resource limited settings [35]. 
DTG-based regimen are highly potent and cost-effective treatment options, although weight 
gain, in particular, in women of African origin under DTG even more aggravated with TAF 
based regimens was described [34, 36]. Nevertheless, altogether in resource limited settings 
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where frequent RNA monitoring is difficult, a first-line therapy with DTG might be safer and 
more reliable in patients presenting with high baseline viral loads.  
The presence of minor InSTI RAMs at baseline was not associated with worse outcome. 
Many of the minor RAMs we detected were present as polymorphisms even before InSTIs 
were introduced into the clinical routine in Europe [37]. L74I and V151I are polymorphic 
mutations. . L74I was most common among subtype A and G infections [38].E157Q is a 
common polymorphic mutation. Other large randomized controlled trials also found that 
InSTIs are effective among patients carrying E157Q mutant viruses [33]. All the other 
mutations we found, including T97A, are known to decrease InSTI susceptibility in 
combination with other mutations [39], which were not present in our patients. Hence, 
although pretreatment minor InSTI resistance associated mutations are common among drug 
naïve HIV-1 infected individuals in Switzerland, it is reassuring that their presence does not 
affect treatment outcome. 
Across all analyses, time to viral suppression was shorter if patients were financially 
independent. There was a trend suggesting that older age at treatment start also decreased the 
risk for failure and the time to suppression. These findings might be explained by better 
adherence in patients with more favorable social conditions and in older patients [40]. In the 
absence of RAMs, non-adherence to therapy has been shown to be the most common reason 
for treatment failure [3]. The proportion of patients reporting decreased adherence in our 
study was also significantly higher in the group that experienced failure. These results show 
that disparities arising from demographic and economic factors in conjunction with 
presumably lower adherence remain relevant even in a cohort that is subject to regular 
follow-up, is based in a high-income country with universal health care access and 
participants being treated with the most potent drug classes. 
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Limitations  
Although the SHCS is highly representative and a considerable number of drug naïve 
participants had an integrase resistance test available, the number of treatment failures was 
small, which may impair the statistical power. We used a cut-off of 50 copies of RNA/mL to 
define a virological failure; the number of events was too small for multivariable analyses 
when we chose a cut-off of 200 or 500 RNA copies/mL. Furthermore, we had predominantly 
male Caucasian participants limiting the generalization of these findings to a more diverse 
group.   
Conclusion 
Many of the risk factors commonly associated with therapeutic failure such as the severity of 
immunodeficiency, stage of the disease and financial situation were still relevant despite the 
potency of InSTIs. The chance of virological failure was consistently associated with the 
baseline viral load and the CD4 count, even in patients on DTG. 
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Tables 
Table 1: Baseline characteristics 
Baseline  characteristics All patients  
n=1’419 
Patients with 
GRT 
n=646 
No minor 
InSTI mutation 
n= 542 
≥1 minor 
InSTI 
mutation 
n= 104   
Median [IQR] age at start of cART 39 [31,49] 38 [30,49] 38 [30,49] 37 [31,47.5] 
Sex (%)     
 Male  1,176 (82.9) 539 (83.4) 457 (84.3) 82 (78.9) 
 Female 243 (17.1) 107 (16.6)   85 (15.7) 22 (21.2) 
Ethnicity (%)     
 White 1,096 (77.2) 508 (78.6) 425 (78.4)    83 (79.8) 
 Black 168 (11.8) 63 (9.8)   47 (8.7) 16 (15.4) 
 Other 155 (10.9) 75 (11.6) 70 (12.9) 5 (4.8) 
Transmission category (%)     
 MSM 842 (59.4) 402 (62.2)      335 (61.8) 67 (64.4) 
 Heterosexual males 241 (17.0) 99 (15.3) 89 (16.4) 10 (9.6) 
 Heterosexual females 195(13.7) 91  (14.1) 71 (13.1) 20 (19.2) 
 intravenous drug use 59  (4.2) 54 (8.4) 47 (8.7) 7 (6.73) 
 Other 81 (5.7)    
Subtype (%)     
 B 364 (25.7) 364 (56.4) 312 (57.6) 52 (50.0) 
 non-B 253 (17.8) 253 (39.2) 204 (37.6) 49 (47.1) 
 n/a 802 (56.5) 29 (4.5) 26 (4.8) 3 (2.9) 
HIV-RNA (%)     
 < 10’000 copies/mL 437 (30.8) 194 (30.0) 161 (29.7) 33 (31.7) 
 10’000-99’999 copies/mL 604 (42.6) 260 (40.3) 218 (40.2) 42 ( 40.4) 
 ≥100’000 copies/mL 378 (26.6) 192 (29.7) 163 (30.1) 29 ( 27.9) 
Log median [IQR] HIV-RNA  
cps/mL 
4.5 [3.5,5.1] 4.5 [3.7,5.2]   
CD4 cell count (%)     
 <200 cells/µL 281 (19.8) 135 (20.9) 106 (19.6) 29 (27.9) 
 200-500 cells/µL 724 (51.0) 306 (47.4) 267 (49.3) 39 (37.5) 
 >500 cells/µL 414 (29.2) 205 (31.7) 169 (31.2) 36 (34.6) 
Median [IQR] CD4 cells/µL 381 [226,549] 391[230,551]   
AIDS defining event at baseline 
(%) 
125 (8.8) 43 (6.7) 35 (6.5) 8 (7.7) 
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InSTI administered (%)     
 RGV 213 (15.0) 67 (10.4) 54 (10.0) 13 (12.5) 
 EVG 281 (19.8) 124 (19.2) 108 (19.9) 16 (15.4) 
 DTG 925 (65.2)  455 (70.4) 380 (70.1) 75 (72.1) 
ART combinations (%)     
 3TC+ABC+DTG  460 (32.4) 227 (35.1) 198 (36.5) 29 (27.9) 
 DTG+ETC+TDF  259 (18.3) 150 (23.2) 120 (22.1) 30 (28.9) 
 DTG+ETC+TAF  143 (10.8) 42 (6.5) 34 (6.3) 8 (7.7) 
 COB+ETC+EVG+TAF 130 (9.2) 53 (8.2) 47 (8.7) 6 (5.8) 
 COB+ETC+EVG+TDF  123 (8.7) 59 (9.1) 50 (9.2) 9 (8.7) 
 ETC+RGV+TDF  126 (8.9) 37 (5.7)  30 (5.5) 7 (6.7) 
 Other drug combinations 178 (11.8) 78 (12.1) 63 (11.6) 15 (14.4) 
Abbreviations: GRT=,genotypic resistance test,  cART= combined antiretroviral treatment,  MSM=Men who 
have sex with men,  RGV=Raltegravir, EVG=Elvitegravir, DTG=Dolutegravir, 3TC=Lamivudine, 
ABC=Abacavir, ETC=Emtricitabin, TDF=Tenofovir, TAF=Tenofovir alafenamid, COB=cobicistat. 
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Figure legends 
Figure 1: Flow diagram of study inclusion. 
Abbreviations: cART, combined antiretroviral therapy; GRT, genotypic resistance test 
 
Figure 2: Multivariable Cox regression. Predictors of virological failure (A) and time to viral 
suppression (B) among drug-naïve HIV-infected individuals (n=1’419) 
Abbreviations: RGV=Raltegravir, EVG=Elvitegravir, DTG=Dolutegravir, InSTI=Integrase 
strand transfer inhibitor, BL=baseline, MSM=men having sex with men, HR=multivariable 
hazard ratio 
 
Figure 3: Kaplan –Meier curves with time to virological failure and time to suppression 
comparing patients by the CD4 cell count (A and B) and HIV-1 RNA copies/mL (C and D) at 
baseline. 
 
Figure 4: Kaplan –Meier curves with time to virological failure and time to suppression 
comparing patients with and without InSTI resistance associated mutations.  
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Figure 1 
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Figure 3 
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Figure 4 
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